EU citizens rally for medical cannabis but face a rigid European Commission

EU citizens rally for medical cannabis but face a rigid European Commission
March 1, 2024

In the EU, access to medical cannabis is a matter of national policy. A group of citizens wants to change that by leveraging a citizens’ initiative and prompting the European Commission to act.

European citizens’ initiative on medical cannabis

In February 2024, a group of organisers succeeded in registering a European citizens’ initiative on medical cannabis. A citizens’ initiative is a form of direct democracy; when a group believes that there is a gap in EU law, they can leverage the procedure set out in Regulation (EU) 2019/788 to prompt the European Commission to take action. The procedure has three phases: first, register the initiative; second, collect the required number of signatures; finally, a hearing takes place in the European Parliament and then the Commission responds.

Not every initiative gets registered as certain conditions must be. This group has completed this first phase, resulting in Commission Implementing Decision (EU) 2024/588. As a next step, the organisers have six months to open the signature collection. If the initiative receives one million statements of support within one year from at least seven different Member States, then they move on to the third and final phase.

The opportunity: improving access to medical cannabis in the EU

The organisers believe that the EU’s prohibitive cannabis policy is misguided and outdated. They refer to changes in the laws of EU member states, UN recommendations and human rights concerns.

The registered initiative has two aims:

  • foster access to medical cannabis, and allow patients to transport cannabis prescribed for therapeutic uses throughout the Union;
  • allocate the necessary resources for researching cannabis for its therapeutic uses.

The initiative’s initial objectives were more ambitious, but they faced a rigid Commission.

The legal obstacles

Trying to evoke change via EU legislation has the obvious benefit of scale: success means change is implemented across the Union. But there is an important caveat. The EU may only act within the limits of the competences conferred upon it by the EU Treaties (TEU and TFEU).

This is where complications arise. The EU’s powers to promote medical cannabis are not particularly firm. Considering the topic from a public health angle, Union action can only complement national policy (Article 168 TFEU). Seen from the criminal law angle, the EU’s powers are limited to establishing minimum rules for drug trafficking (Article 83 TFEU, see for example Council Framework Decision 2004/757/JHA). This is not to say that change at the EU legislative level is impossible, far from it. But change requires creativity and a willing legislator; and at this point, the Commission is not showing any appetite.

When the group of organisers presented their initial list of objectives, the Commission pushed back on their ambition. For example, the group also called on the Commission to relax criminal and administrative penalties for adult use, possession, and the cultivation of cannabis for personal purposes. The Commission refused to make this part of the initiative, commenting that excluding conduct from being deemed criminal exceeds its powers. Furthermore, in a recent response to a parliamentary question,  the Commission firmly stated that it has no plans to propose further harmonisation regarding medical cannabis within the EU’s legal framework.

So, what can be expected from the initiative? If it reaches one million signatures, then the Commission must respond but is not under an obligation to take affirmative action. One possible outcome is that the Commission proposes a Council recommendation to promote access to medical cannabis. Harmonisation of national legislation is, however, not on the agenda.

Cannabis policy is slowly changing in the EU but primarily through national efforts. The EU citizens’ initiative on medical cannabis presents a rare opportunity to evoke change at the EU level. The initiative also brings to light legal challenges. The EU’s powers to promote medical cannabis are not very strong, with the Commission displaying little appetite to take the lead. If the citizens’ initiative reaches one million signatures, then the Commission will have to respond. One possible outcome is that the Commission proposes a Council recommendation to promote access to medical cannabis.

If you would like any further information about this legal development, then please contact Bregt Raus.

Written by

  • Bregt Raus

    Managing Associate

Recommended articles

March 17, 2025

The new Belgian government’s public health policy: 10 key take-aways for pharma policy

The new Belgian federal government has outlined its vision for public health in a policy paper under the slogan “More money for health, more health for our money”. Public health is a high-priority sector with a significant budget, and the policy paper introduces several key measures that will shape the pharmaceutical industry in the coming years. For pharma companies operating in Belgium, these developments bring both new regulatory challenges and strategic opportunities. Here is a focused analysis of ten key changes and their potential impact on the pharma industry.

Read on
March 13, 2025

CJEU’s DocMorris Ruling: where is the line for pharmaceutical advertising?

The intersection of pharmaceutical advertising, consumer protection, and internal market freedoms remains a complex legal battleground within the EU. In Apothekerkammer Nordrhein v. DocMorris NV (C-517/23), the Court of Justice of the European Union (CJEU) revisited the meaning of ‘advertising of medicinal products’, clarifying how far national restrictions on pharmaceutical advertisements can go under EU pharmaceutical law and internal market principles.

Read on
February 12, 2025

New year, new policy: CPVO updates its public access to documents policy

The Community Plant Variety Office (CPVO) recently revised its public access to documents policy to align with the European Union (EU)’s evolving transparency standards. Effective since 15 January 2025, the new policy seeks to ensure broad access to all documents that the CPVO holds, while protecting private parties’ commercial interests. In particular, a system of prior confidentiality requests has been put in place for applicants of Community plant variety rights (CPVR).

Read on